Cardiovascular Needle Market Size, Trends and Growth Analysis by 2027

The cardiovascular needle market was valued at approximately US$ 84.429 million in 2021 and is anticipated to grow to US$ 137.855 million by 2028, reflecting a compound annual growth rate (CAGR) of 7.3% from 2021 to 2028.

This growth can be attributed to several factors, including the rising incidence of cardiovascular diseases (CVDs) and an increasing elderly population. However, the market may face challenges due to a growing preference for surgical staples over traditional cardiovascular needles.

Cardiovascular needles are essential tools used in various surgical procedures, including open-heart surgeries, cardiac valve replacements, heart transplants, and coronary artery bypass graft surgeries. These needles are categorized into two types: single-use (eyeless) needles and multiple-use (eyed) needles. They are typically manufactured from advanced stainless-steel alloys that contain high levels of nickel, as well as materials like Surgalloy and Ethalloy.

CVDs encompass a range of disorders affecting the heart and blood vessels, including cerebrovascular diseases, coronary heart disease, and rheumatic heart disease. Major lifestyle factors contributing to the risk of CVDs include tobacco use, poor dietary habits, and lack of physical activity, all of which can lead to heart attacks and strokes. Other significant risk factors include hypertension, diabetes, and elevated cholesterol levels. CVDs rank among the leading causes of death globally. According to the World Health Organization (WHO), they are the foremost cause of mortality worldwide. In 2016, approximately 17.9 million people died from CVDs, accounting for 31.0% of total deaths that year, with around 85% of these fatalities resulting from heart attacks and strokes. The primary causes of these conditions include fat deposits in blood vessels that obstruct blood flow to the heart or brain, as well as bleeding vessels or blood clots in the brain.

As per the European Cardiovascular Disease Statistics 2017, CVDs are responsible for over 3.9 million deaths annually in Europe, with more than 1.8 million of those occurring in the European Union (EU). This translates to 45.0% and 37.0% of total mortality in Europe and the EU, respectively. Furthermore, the American Heart Association (AHA) reported in 2019 that approximately 121.5 million adults in the United States, or about 50% of the adult population, are affected by CVDs each year. The Journal of the American College of Cardiology highlights that Asia is experiencing a rising prevalence of high blood pressure, diabetes, and elevated cholesterol levels, with countries like Japan, China, and India being significant contributors to the overall incidence of CVDs in the region.

The increasing prevalence of CVDs globally is driving the demand for diagnostic and therapeutic cardiovascular devices, thereby propelling the growth of the cardiovascular needle market.

The COVID-19 pandemic has posed unprecedented challenges worldwide, straining healthcare systems and necessitating the prioritization of limited resources to reduce hospital admissions. Cardiac surgical patients are particularly vulnerable, requiring critical ICU resources and facing a higher risk of COVID-19 complications. Consequently, many hospitals and surgical centers have had to cancel or postpone elective surgeries, including cardiovascular procedures. This has led to a short-term negative impact on the cardiovascular needle market. However, as vaccination efforts progress and transmission rates decline, healthcare systems are expected to normalize, leading to an increased demand for cardiovascular needles in the long run.

The cardiovascular needle market is categorized by type into round-bodied needles and cutting needles. The round-bodied needles segment is projected to hold a larger market share in 2021, while the cutting needles segment is expected to exhibit a higher CAGR during the forecast period.

In terms of application, the market is divided into open-heart surgery and cardiac valve procedures. The open-heart surgery segment is anticipated to dominate the market in 2021 and is expected to grow at a faster rate from 2021 to 2028, driven by the increasing number of open-heart surgeries performed globally.

Regarding usage, the market is segmented into single-use and multiple-use needles. The single-use segment is projected to capture a larger market share in 2021 and is expected to grow at a higher CAGR through 2028.

Finally, by end user, the cardiovascular needle market is divided into hospitals and clinics, ambulatory surgical centers, and cardiovascular centers. The hospitals and clinics segment is expected to hold the largest market share in 2021 and is also projected to register the highest CAGR during the forecast period.

Key sources of information for this report include the American Heart Association, European Cardiovascular Disease Statistics, the Journal of the American College of Cardiology, the National Health Service, the Food and Drug Administration, the World Health Organization, the Centers for Disease Control and Prevention, and various national cardiovascular disease registries.